Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.

Alessandra Bearz,Isabella Garassino,Raffaele Cavina,Adolfo Favaretto,Massimo Boccalon,Renato Talamini,Massimiliano Berretta,Simon Spazzapan,Cecilia Simonelli,Armando Santoro,Umberto Tirelli

Lung Cancer（2008）

引用 34|浏览34

暂无评分

摘要

Several drugs have been approved for the treatment of patients affected by advanced non-small cell lung cancer (NSCLC) in progression after first line chemotherapy: Docetaxel, Pemetrexed and Erlotinib. Poor gain of survival has been demonstrated in randomised trials and patient characteristics predicting activity are poorly known yet.

查看译文

关键词

Non-small cell lung cancer,Second-line,Chemotherapy,Pemetrexed

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要